α1-Acid Glycoprotein in Late-Life Depression: Relationship to Medical Burden and Genetics

Journal of Geriatric Psychiatry and Neurology

Volumn 16, Issue 4, 2003, Pages 235-239

  Adeoye, Opeolu M ^a   Ferrell, Robert E ^b   Kirshner, Margaret A ^c   Mulsant, Benoit H ^d   Seligman, Karen ^c   Begley, Amy E ^c   Reynolds III, Charles F ^c   Pollock, Bruce G ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

1 acid glycoprotein; AAG; CIRS G; Late life depression

Indexed keywords

ALPHA1 GLYCOPROTEIN; ANTIDEPRESSANT AGENT; DNA; NORTRIPTYLINE; OROSOMUCOID; PAROXETINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE; AGED; ALLELE; ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE SEVERITY; DNA DETERMINATION; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MENTAL HEALTH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; SCORING SYSTEM; BLOOD; COGNITIVE DEFECT; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; GENE EXPRESSION; GENETICS; HOSPITALIZATION; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COGNITION DISORDERS; COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NORTRIPTYLINE; OROSOMUCOID; PAROXETINE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 0345303858     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/0891988703258321     Document Type: Article

References (16)

1. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40:1-47.
2. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metabol Rev 2001; 33(2):161-235.
3. Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochimica Biophysica Acta 2000; 1482:157-171.
4. Nemeroff CB, Krisnan RR, Blazer DG, et al. Elevated plasma concentrations of alpha-1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site, in depressed patients. Arch Gen Psychiatry 1990; 47:337-340.
5. Healy D, Calvin J, Whitehouse AM, et al. Alpha-1-acid glycoprotein in major depressive and eating disorders. J Affect Disord 1991; 22:13-20.
6. Henry OF, Blacher J, Verdavaine J, et al. Alpha 1-acid glycoprotein is an independent predictor of in-hospital death in the elderly. Age Ageing 2003; 32:37-42.
7. Kehoe WA, Kwentus JA, Sheffel WB, Harralson AF. Increased alpha-1-acid glycoprotein in depression lowers free fraction of imipramine. Biol Psychiatry 1991; 29:489-493.
8. Nieto E, Vieta E, Alvarez L, et al. Alpha-1-acid glycoprotein in major depressive disorder: relationships to severity, response to treatment and imipramine plasma levels. J Affect Disord 2000; 59:159-164.
9. Young RC, Patel A, Meyers BS, et al. Alpha-1-acid glycoprotein, age, and sex in mood disorders. Am J Geriatr Psychiatry 1999; 7(4):331-334.
10. Blain PG, Mucklow JC, Rawlins MD, et al. Determinants of plasma alpha-1-acid glycoprotein concentrations in health [abstract]. Br J Clin Pharmacol 1981; 12:275.
11. Abernathy DR, Kerzner L. Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. J Am Geriatr Soc 1984; 32:705-708.
12. Yuasa I, Umetsu K, Suenaga K, Robinet-Levy M. Orosomucoid (ORM) typing by isoelectric focusing: evidence for two structural loci ORM1 and ORM2. Hum Genet 1986; 74:160-161.
13. Yuasa I, Umetsu K, Vogt U, et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 1997; 99:393-398.
14. Folstein MF, Folstein SE, McHigh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
15. Mulsant BH, Pollock BG, Nebes R, et al. A double-blind, randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: six-week outcome. J Clin Psychiatry 1999; 60:16-20.
16. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999; 60:9-15.